DNA
Ginkgo Bioworks Holdings, Inc. [DNA] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
DNA Stock Summary
Top 10 Correlated ETFs
DNA
Top 10 Correlated Stocks
DNA
In the News
DNA Financial details
Company Rating
-
Market Cap
2.17B
Income
-892.87M
Revenue
251.46M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1.22K
Optionable
No
Shortable
Yes
Earnings
29 Feb 2024
P/E
-3.44
Forward P/E
-
PEG
0.55
P/S
10.16
P/B
2.35
P/C
-
P/FCF
-7.89
Quick Ratio
6.6
Current Ratio
6.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.47
EPS next Y
-
EPS next Q
-
EPS this Y
-63.2%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
41.64%
Revenue last 5Y
35.93%
Revenue Q/Q
-37.3%
EPS Q/Q
-31.25%
-
-
-
-
SMA20
7.14%
SMA50
29.72%
SMA100
-20.29%
Inst Own
-
Inst Trans
-
ROA
-42%
ROE
-56%
ROC
-0.5%
Gross Margin
75%
Oper. Margin
-292%
Profit Margin
-272%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.993-2.545
52W High
-
52W Low
-
RSI
60.22
Rel Volume
0.04
Avg Volume
22.47M
Volume
952.51K
Perf Week
18.25%
Perf Month
28.45%
Perf Quarter
1.71%
Perf Half Y
-16.45%
-
-
-
-
Beta
1.357
-
-
Volatility
0.87%, 0.74%
Prev Close
-3.77%
Price
8.94
Change
-5.99%
Company Profile
- Volume Average 22.47M
- Market Capitalization 2.17B
- Employee 1.22K
- CEO Dr. Jason Kelly
- Headquarters Boston,MA,US
- IPO Date 2021-04-19
-
Website
https://www.ginkgobioworks.com 
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
